Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has found.
The new review examined data from 17 clinical trials with a total of 20,342 participants, all looking at the impact of anti-amyloid drugs on people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Proponents of these drugs have theorized that they would be more effective at these earlier stages before the disease has progressed.
Please read the details here: https://www.cochrane.org/about-us/news/anti-amyloid-alzheimers-drugs-show-no-clinically-meaningful-effect
Image: unsplash